Remission Rate in the Patients with Graves' Disease after Treatment with a Minimum Maintenance Dose of Methimazole for 12 Months

被引：0
|
作者：
Mutsuo, Beniko [1 ]
Hiroyuki, Ikawa [1 ]
Takayuki, Mori [1 ]
Yasuo, Mashio [2 ]
机构：
[1] Sapporo Kosei Gen Hosp, Sapporo, Hokkaido, Japan
[2] Sapporo Kosei Kyosai Clin, Sapporo, Hokkaido, Japan
来源：
ENDOCRINE REVIEWS | 2014年 / 35卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
MON-0471
引用
收藏
页数：3
相关论文
共 50 条
  • [31] MAINTENANCE OF REMISSION WITH CORTICOSTEROID TREATMENT IN PATIENTS WITH CROHNS-DISEASE
    BRIGNOLA, C
    LANFRANCHI, GA
    CAMPIERI, M
    BAZZOCCHI, G
    FARRUGGIA, P
    TRAGNONE, A
    IANNONE, P
    PASQUALI, S
    DIGESTIVE DISEASES AND SCIENCES, 1986, 31 (10) : S460 - S460
  • [32] Serum T3 Level and Duration of Minimum Maintenance Dose Therapy Predict Relapse in Methimazole-Treated Graves Disease (vol 5, bvaa170, 2021)
    Thewjitcharoen, Y.
    Karndumri, K.
    Chatchomchuan, W.
    Porramatikul, S.
    Krittiyawong, S.
    Wanothayaroj, E.
    Butadej, S.
    Nakasatien, S.
    Rajatanavin, R.
    Himathongkam, T.
    JOURNAL OF THE ENDOCRINE SOCIETY, 2021, 5 (04)
  • [33] IN EARLY UNDIFFERENTIATED ARTHRITIS AUTOANTIBODIES AND POWER DOPPLER IDENTIFY PATIENTS ACHIEVING REMISSION AFTER 12 MONTHS OF TREATMENT
    Sakellariou, G.
    Scire, C. A.
    Balduzzi, S.
    Fusetti, C.
    Caporali, R.
    Montecucco, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 270 - 270
  • [34] Predictors of time to remission and treatment failure in patients with Graves' disease treated with propylthiouracil
    Cinemre, Hakan
    Bilir, Cemil
    Gokosmanoglu, Feyzi
    Akdemir, Nermin
    Erdogmus, Besir
    Buyukkaya, Ramazan
    CLINICAL AND INVESTIGATIVE MEDICINE, 2009, 32 (03): : E199 - E205
  • [35] CHANGES OF CIRCULATING THYROID AUTOANTIBODY LEVELS DURING AND AFTER THERAPY WITH METHIMAZOLE IN PATIENTS WITH GRAVES-DISEASE
    MARCOCCI, C
    CHIOVATO, L
    MARIOTTI, S
    PINCHERA, A
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1982, 5 (01) : 13 - 19
  • [36] Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study
    Howarth, D
    Epstein, M
    Lan, L
    Tan, P
    Booker, J
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (10) : 1489 - 1495
  • [37] Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study
    Douglas Howarth
    Martin Epstein
    Linda Lan
    Phillip Tan
    John Booker
    European Journal of Nuclear Medicine, 2001, 28 : 1489 - 1495
  • [38] Oxidative stress peripheral parameters in Graves' disease: the effect of methimazole treatment in patients with and without infiltrative ophthalmopathy
    Bednarek, J
    Wysocki, H
    Sowinski, J
    CLINICAL BIOCHEMISTRY, 2005, 38 (01) : 13 - 18
  • [39] Maintenance of remission after treatment with Exclusive Enteral Nutrition and Azathioprine in paediatric patients with Crohn's disease
    Pujol Muncunill, G.
    Pascual-Perez, A. I.
    Dominguez-Sanchez, P.
    Feo-Ortega, S.
    Suarez-Galvis, M.
    Vila-Miravet, V.
    Martin de Carpi, F. J.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S517 - S517
  • [40] Letter to the Editor: Remission of Graves' Disease After Initiation of Ocrelizumab in Patients with Multiple Sclerosis
    Casany-Fernandez, Rosa
    Gascon-Gimenez, Francisco
    Matarredona Solaz, Enrique Juan
    Pardo Lozano, Felipe
    Dominguez-Moran, Jose Andres
    Ferri Ciscar, Jordi
    Real Collado, Jose Tomas
    THYROID, 2023, 33 (02) : 267 - 269
12345